Cytokinetics Inc (CYTK) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.

Total Cash From Operating Activities Chart for Cytokinetics Inc

Cytokinetics Inc (CYTK) operating cash flow for FY2025 was USD -510.0M. Cytokinetics Inc's operating cash flow moved from USD -22.3M in 2002 to USD -510.0M in 2025 over 23 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$8.53B
Implied Share Price
$61.35
Enterprise Value
$9.26B
Revenue (TTM)
$67.67M
EBITDA
-$695.36M
Profit Margin
0.00%
Trailing P/E
—
Forward P/E
117.65
Price/Book (MRQ)
60.31
Price/Sales (TTM)
126.04
EV/EBITDA
-15.82
EV/Revenue
145.20
Dividend Yield
—
Book Value
$-1.25
Free Cash Flow (FY2025)
-$534.82M
Free Cash Flow Yield
-6.27%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.